The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Cardiovascular Genetic Testing Market Projected To Reach By 2030?
The cardiovascular genetic testing market size has recently experienced rapid expansion. This market is projected to grow from $3.93 billion in 2025 to $4.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. Historically, this growth can be attributed to several factors including increasing awareness of inherited cardiovascular disorders, the expansion of molecular diagnostic capabilities, the declining costs of genetic sequencing, the growing use of genetic counseling services, and increased research in cardiovascular genomics.
The cardiovascular genetic testing market size is projected to experience significant expansion in the coming years, with an expected increase to $6.62 billion by 2030, reflecting a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period is primarily driven by the escalating demand for precision medicine, the rising acceptance of population-based genetic screening, the expanding use of AI in variant interpretation, the increasing integration of genomics into clinical decision-making, and a heightened focus on preventive cardiovascular healthcare. Major developments anticipated in this period include the increased adoption of predictive genetic risk assessment, the rising utilization of multigene panel testing, the deeper integration of bioinformatics and AI analytics, the broadening applications of pharmacogenomic testing, and an enhanced emphasis on personalized cardiovascular care.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp
Which Key Factors Are Driving The Cardiovascular Genetic Testing Market Growth?
The escalating incidence of cardiovascular diseases is projected to spur the expansion of the cardiovascular genetic testing market in the foreseeable future. Cardiovascular diseases (CVDs) represent a category of ailments affecting the heart and blood vessels, encompassing conditions such as heart attacks, strokes, and hypertension. The rise in cardiovascular disease prevalence is primarily due to increasingly sedentary lifestyles linked to urbanization, which contribute to conditions like obesity, hypertension, and various metabolic disorders. This growing occurrence of cardiovascular diseases boosts the demand for cardiovascular genetic testing, as early detection of genetic risks allows for personalized prevention and treatment strategies aimed at diminishing the likelihood of severe heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Thus, the rising prevalence of cardiovascular disease is a significant catalyst for the growth of the cardiovascular genetic testing market.
Which Segment Classifications Are Used In The Cardiovascular Genetic Testing Market Segment Analysis?
The cardiovascular genetic testing market covered in this report is segmented –
1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types
2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases
3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing
4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications
5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing
Subsegments:
1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing
2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing
3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing
4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing
5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing
6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing
Which Trends Are Guiding The Direction Of The Cardiovascular Genetic Testing Market?
Leading companies within the cardiovascular genetic testing market are prioritizing the creation of novel solutions, such as clinician-ordered tests. These tests aim to confirm medical necessity and customize testing to a patient’s specific health status, thereby cutting down on redundant testing and expenses. A clinician-ordered test is a medical examination or diagnostic process initiated by a healthcare professional to assess, monitor, or guide a patient’s health management. For instance, in September 2025, Mass General Brigham, a US-based integrated academic healthcare system, in partnership with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test. This test assesses the inherited risk for eight cardiovascular conditions, including atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Offered on a self-pay basis, its development leveraged genotype and clinical data from 236,393 individuals from the NIH’s All of Us Research Program. The integration of publicly available polygenic risk scores for each condition was achieved using PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is gathered through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine is responsible for interpreting the findings and generating patient-friendly reports.
Which Firms Are Contributing To The Cardiovascular Genetic Testing Market Ecosystem?
Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.
Get The Full Cardiovascular Genetic Testing Market Report:
https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report
Which Region Has The Greatest Market Share In The Cardiovascular Genetic Testing Market?
North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cardiovascular Genetic Testing Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=33054&type=smp
Browse Through More Reports Similar to the Global Cardiovascular Genetic Testing Market 2026, By The Business Research Company
Cardiovascular Clinical Trials Market Report 2026
Genetic Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report
Direct To Consumer Dtc Genetic Testing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model